Access Pharmaceuticals, Inc. (ACCP) Partner Receives China Regulatory and Marketing Approval for MuGard
Access Pharmaceuticals Inc., a biopharm company focused on the development of treatments in the areas of oncology, diabetes, and RNAi, today announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., has received regulatory approval from the State Food and Drug Administration (SFDA) to market MuGard in China. China’s regulatory agency approved MuGard to treat cancer patients afflicted with oral mucositis a debilitating side effect of many anticancer treatments. The approval provides Access the opportunity to tap into an expansive market with a largely unmet medical need. Access will soon begin manufacturing MuGard in the United States to meet…